(Q51556494)

7 April 2018

title

Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. (English)

1 reference

7 April 2018

1 reference

1 reference

Steven J Potts

1

1 reference

7 April 2018

Joseph S Krueger

2

1 reference

7 April 2018

Nicholas D Landis

3

1 reference

7 April 2018

David A Eberhard

4

1 reference

7 April 2018

G David Young

5

1 reference

7 April 2018

Steven C Schmechel

6

1 reference

7 April 2018

Holger Lange

7

1 reference

7 April 2018

publication date

16 July 2012

1 reference

7 April 2018

published in

Laboratory Investigation

1 reference

7 April 2018

volume

92

1 reference

7 April 2018

issue

9

1 reference

7 April 2018

page(s)

1342-1357

1 reference

7 April 2018

https://scigraph.springernature.com/pub.10.1038/labinvest.2012.91

exact match

0 references

cites work

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

The Clinical Importance of the Heterogeneity of HER2 neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

21 January 2018

Measurement of Diversity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

R: A Language for Data Analysis and Graphics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Dynamic and modern: bringing the ethics of phase I trials up to date.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

What do we learn from HER2-positive breast cancer genomic profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Breast tumor heterogeneity: causes and consequences

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

The apportionment of quadratic entropy: a useful alternative for partitioning diversity in ecological data

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

HER2 genetic heterogeneity in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Gastric cancer heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2012.91

7 January 2021

10.1038/LABINVEST.2012.91

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

22801299

1 reference

7 April 2018